文献速递淋巴瘤浆细胞疾病

地塞米松、利妥昔单抗和环磷酰胺治疗复发和/或难治及初治华氏巨球蛋白血症患者

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
PubMed 文献 · Br J Haematol · 2017-08-08

该研究评估了DRC方案(地塞米松、利妥昔单抗、环磷酰胺)治疗100例华氏巨球蛋白血症患者的疗效,其中50例为复发/难治患者。复发/难治组总缓解率87%,中位无进展生存期32个月,中位至下次治疗时间50个月;初治组总缓解率96%,中位无进展生存期34个月。缓解率和结局与MYD88突变状态无关。

要点

  • 复发/难治组总缓解率87%,中位无进展生存期32个月,中位至下次治疗时间50个月。
  • 初治组总缓解率96%,中位无进展生存期34个月,中位至下次治疗时间未达到。
  • 29例可检测基因型患者中25例(86%)携带MYD88L265P突变,缓解率和结局与MYD88突变状态无关。

核心结论

  • 与初治背景相似,DRC是华氏巨球蛋白血症有效且耐受性良好的挽救方案。
  • 与伊布替尼相比,DRC提供了一种费用更低、固定疗程的选择,初步数据提示其疗效与患者MYD88状态无关。

研究设计与样本

  • 研究纳入2007年1月至2014年12月间接受DRC治疗的100例华氏巨球蛋白血症患者,其中50例为复发/难治患者。
  • 对29例患者进行MYD88L265P突变状态检测。

主要发现

  • 总体缓解率为87%。
  • 中位无进展生存期为32个月(95%CI:15-51),中位至下次治疗时间为50个月(95%CI:35-60)。
  • 初治队列(n=50)总缓解率为96%,中位无进展生存期为34个月(95%CI:23-未达到),中位至下次治疗时间未达到(95%CI:37-未达到)。
  • 29例可检测基因型患者中25例(86%)携带MYD88L265P突变,缓解率和结局与MYD88突变状态无关。
  • ≥3级不良事件包括中性粒细胞减少(20%)、血小板减少(7%)和感染(3%)。

临床怎么用

  • 作者认为,DRC是华氏巨球蛋白血症有效且耐受性良好的挽救方案,与伊布替尼相比提供了一种费用更低、固定疗程的选择,初步数据提示其疗效与患者MYD88状态无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of Waldenström macroglobulinaemia (WM) relies predominantly on small trials, one of which has demonstrated activity of dexamethasone, rituximab and cyclophosphamide (DRC) in the frontline setting. We report on the efficacy of DRC, focusing on relapsed/refractory (R/R) patients. Ibrutinib, a recently approved agent in WM demonstrated limited activity in patients with MYD88WT genotype. Herein, we additionally report on the activity of DRC based on the MYD88L265P mutation status. Of 100 WM patients evaluated between January 2007 and December 2014 who received DRC, 50 had R/R WM. The overall response rate (ORR) was 87%. The median progression-free survival (PFS) and time-to-next-therapy (TTNT) were 32 (95% confidence interval [CI]: 15-51) and 50 (95% CI: 35-60) months, respectively. In the previously untreated cohort (n = 50), the ORR was 96%, and the median PFS and TTNT were 34 months (95% CI: 23-not reached [NR]) and NR (95% CI: 37-NR), respectively. Twenty-five (86%) of 29 genotyped patients harbored MYD88L265P . The response rates and outcomes were independent of MYD88 mutation status. Grade ≥3 adverse effects included neutropenia (20%), thrombocytopenia (7%) and infections (3%). Similar to the frontline setting, DRC is an effective and well-tolerated salvage regimen for WM. In contrast to ibrutinib, DRC offers a less expensive, fixed-duration option, with preliminary data suggesting efficacy independent of the patients' MYD88 status.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Paludo J, Abeykoon JP, Kumar S, et al. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. Br J Haematol. 2017. PMID: 28786474. doi:10.1111/bjh.14826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。